Galectin Therapeutics

Galectin Therapeutics company information, Employees & Contact Information

Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. We use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis, tumor vaccine enhancement, and colorectal cancer. We also have a colorectal cancer program moving towards commercialization in foreign locations based on medical needs in those regions.

Company Details

Employees
40
Founded
-
Address
4960 Peachtree Industrial Boulevard,
Phone
(678) 620-3186
Email
sh****@****ics.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Norcross, GA
Looking for a particular Galectin Therapeutics employee's phone or email?

Galectin Therapeutics Questions

News

Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference - Stock Titan

Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference Stock Titan

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update - Yahoo Finance

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2025 and Provides Business Update Yahoo Finance

Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment - Nasdaq

Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment Nasdaq

Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference - The Manila Times

Galectin Therapeutics to Present at the H.C. Wainwright 9th Annual MASH Investor Conference The Manila Times

Prevents Varices at 18 Months — Galectin Therapeutics to Present NAVIGATE Data at AASLD Nov 10 - Stock Titan

Prevents Varices at 18 Months — Galectin Therapeutics to Present NAVIGATE Data at AASLD Nov 10 Stock Titan

Galectin Therapeutics Reports Positive NAVIGATE Trial Results for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension - Quiver Quantitative

Galectin Therapeutics Reports Positive NAVIGATE Trial Results for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension Quiver Quantitative

Belapectin Misses Primary Endpoint in Phase 3 MASH Cirrhosis, Portal Hypertension Trial - HCPLive

Belapectin Misses Primary Endpoint in Phase 3 MASH Cirrhosis, Portal Hypertension Trial HCPLive

Freeman buys Galectin therapeutics (GALT) stock worth $14,495 - Investing.com

Freeman buys Galectin therapeutics (GALT) stock worth $14,495 Investing.com

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 - Yahoo Finance

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 Yahoo Finance

Biotech Leader Galectin Therapeutics Takes Stage at H.C. Wainwright Global Investment Conference in NYC - Stock Titan

Biotech Leader Galectin Therapeutics Takes Stage at H.C. Wainwright Global Investment Conference in NYC Stock Titan

Galectin Therapeutics Appoints Khurram Jamil, M.D. To Chief Medical Officer - citybiz

Galectin Therapeutics Appoints Khurram Jamil, M.D. To Chief Medical Officer citybiz

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension - Yahoo Finance

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension Yahoo Finance

EX-99.1 - SEC.gov

EX-99.1 SEC.gov

Ben Carson joins Galectin Therapeutics as ‘special consultant’ - drugdiscoverytrends.com

Ben Carson joins Galectin Therapeutics as ‘special consultant’ drugdiscoverytrends.com

Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update - citybiz

Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update citybiz

Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials - Yahoo Finance

Galectin Therapeutics Inc. (GALT) Surges on Promising Belapectin Trial Data and Strong Financials Yahoo Finance

Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients - Stock Titan

Breakthrough: Galectin's MASH Drug Shows 68% Disease Reduction in US Patients Stock Titan

Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show" - Yahoo Finance

Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show" Yahoo Finance

GALT Stock Price and Chart — NASDAQ:GALT - TradingView

GALT Stock Price and Chart — NASDAQ:GALT TradingView

Cracking the Enigma of Fatty Liver Disease - Genetic Engineering and Biotechnology News

Cracking the Enigma of Fatty Liver Disease Genetic Engineering and Biotechnology News

Top Galectin Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant